New Zealand markets closed

Immunovant, Inc. (IMVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
31.48+0.55 (+1.78%)
At close: 04:00PM EDT
31.48 0.00 (0.00%)
After hours: 04:55PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.57B
Enterprise value 3.88B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)6.73
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.75
52-week change 348.42%
S&P500 52-week change 326.36%
52-week high 345.58
52-week low 318.16
50-day moving average 330.27
200-day moving average 332.64

Share statistics

Avg vol (3-month) 31.11M
Avg vol (10-day) 3744.84k
Shares outstanding 5145.29M
Implied shares outstanding 6145.29M
Float 864.26M
% held by insiders 155.53%
% held by institutions 148.48%
Shares short (30 Apr 2024) 48.96M
Short ratio (30 Apr 2024) 48.12
Short % of float (30 Apr 2024) 412.82%
Short % of shares outstanding (30 Apr 2024) 46.17%
Shares short (prior month 28 Mar 2024) 49.02M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Mar 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-27.15%
Return on equity (ttm)-44.51%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -253.37M
Net income avi to common (ttm)-243.45M
Diluted EPS (ttm)-1.81
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)690.94M
Total cash per share (mrq)4.76
Total debt (mrq)306k
Total debt/equity (mrq)0.05%
Current ratio (mrq)22.14
Book value per share (mrq)4.68

Cash flow statement

Operating cash flow (ttm)-210.32M
Levered free cash flow (ttm)-125.81M